68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles)

N/A

Report date: 2025/11/21 17:15:38

Base Information

Drug Name68Ga-anti-HER2 nanobodies (Universite Libre de Bruxelles)

Drug Alias Name68Ga-anti-HER2 nanobodies (imaging, breast cancer)

ClassificationDiagnostic agent (In vivo)Biologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnostics +[6]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversite Libre De Bruxelles

China Registration ClassN/A

Develop Information

Active CompaniesUniversite Libre De Bruxelles

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A